AMEERA 5
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Closed to Enrollment, Patients in Follow-Up